摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

2-异丙基磺酰乙胺 | 320337-16-4

中文名称
2-异丙基磺酰乙胺
中文别名
——
英文名称
2-(isopropylsulphonyl)ethan-1-amine
英文别名
iso-propylsulfonylethylamine;2-(Isopropylsulfonyl)ethanamine;2-propan-2-ylsulfonylethanamine
2-异丙基磺酰乙胺化学式
CAS
320337-16-4
化学式
C5H13NO2S
mdl
MFCD06213263
分子量
151.23
InChiKey
FPMDQMBQVDRLPN-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 沸点:
    298.2±23.0 °C(Predicted)
  • 密度:
    1?+-.0.06 g/cm3(Predicted)

计算性质

  • 辛醇/水分配系数(LogP):
    -0.5
  • 重原子数:
    9
  • 可旋转键数:
    3
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    1.0
  • 拓扑面积:
    68.5
  • 氢给体数:
    1
  • 氢受体数:
    3

安全信息

  • 危险等级:
    IRRITANT
  • 海关编码:
    2921199090

SDS

SDS:f8c1c81dcb8358b62c0db9ccf8529cdf
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    参考文献:
    名称:
    Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series
    摘要:
    Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.05.090
  • 作为产物:
    描述:
    2-(异丙基硫代)乙胺 在 palladium on activated charcoal Oxone氢气碳酸氢钠 作用下, 以 甲醇乙醇N,N-二甲基甲酰胺 为溶剂, 生成 2-异丙基磺酰乙胺
    参考文献:
    名称:
    Optimization and SAR for dual ErbB-1/ErbB-2 tyrosine kinase inhibition in the 6-furanylquinazoline series
    摘要:
    Synthetic modifications on a 6-furanylquinazoline scaffold to optimize the dual ErbB-1/ErbB-2 tyrosine kinase inhibition afforded consistent SAR whereby a 4-(3-fluorobenzyloxy)-3-haloanilino provided the best enzyme potency and cellular selectivity. Changes made to the 6-furanyl group had little impact on the enzyme activity, but appeared to dramatically affect the cellular efficacy. The discovery of lapatinib emerged from this work. (c) 2006 Elsevier Ltd. All rights reserved.
    DOI:
    10.1016/j.bmcl.2006.05.090
点击查看最新优质反应信息

文献信息

  • Anilinoquinazolines as protein tyrosine kinase inhibitors
    申请人:Cockerill George Stuart
    公开号:US06933299B1
    公开(公告)日:2005-08-23
    Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    杂环芳香族化合物被描述,包括它们的制备方法、含有它们的药物组合物、使用方法以及它们在药物中的用途。特别是,本发明涉及喹唑啉和吡啶嘧啶衍生物,这些衍生物表现出蛋白酪氨酸激酶的抑制作用。
  • ESTRA-1,3,5(10),16-TETRAENE-3-CARBOXAMIDES FOR INHIBITION OF 17.BETA.-HYDROXYSTEROID DEHYDROGENASE (AKR1 C3)
    申请人:BAYER PHARMA AKTIENGESELLSCHAFT
    公开号:US20160024142A1
    公开(公告)日:2016-01-28
    The invention relates to AKR1C3 inhibitors of formula (I) and to processes for preparation thereof, to the use thereof for treatment and/or prophylaxis of diseases and to the use thereof for production of medicaments for treatment and/or prophylaxis of diseases, especially of bleeding disorders and endometriosis.
    该发明涉及式(I)的AKR1C3抑制剂,以及其制备方法,用于治疗和/或预防疾病,以及用于生产治疗和/或预防疾病的药物,特别是出血性疾病和子宫内膜异位症。
  • Anilinoquinazaolines as protein tyrosine kianse inhibitors
    申请人:Cockerill Stuart George
    公开号:US20050143401A1
    公开(公告)日:2005-06-30
    Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    本发明涉及异芳香化合物、其制备方法、含有它们的药物组合物、使用方法以及它们在药物中的应用。具体而言,本发明涉及能够抑制蛋白酪氨酸激酶的喹唑啉和吡啶并嘧啶衍生物。
  • Heterocyclic compounds
    申请人:SmithKline Beecham Corporation
    公开号:US07265123B2
    公开(公告)日:2007-09-04
    Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    本发明描述了杂环芳香化合物、其制备方法、包含它们的制药组合物、使用方法以及它们在药物中的应用。特别地,该发明涉及对蛋白酪氨酸激酶抑制作用的喹唑啉和吡啶并嘧啶衍生物。
  • HETEROCYCLIC COMPOUNDS
    申请人:Cockerill Stuart George
    公开号:US20080004294A1
    公开(公告)日:2008-01-03
    Heteroaromatic compounds are described, methods for their preparation, pharmaceutical compositions containing them, methods of use, and their use in medicines. In particular, the invention relates to quinazoline and pyridopyrimidine derivatives which exhibit protein tyrosine kinase inhibition.
    本发明涉及杂环芳香化合物、其制备方法、含有它们的药物组合物、使用方法以及它们在药物中的应用。特别地,本发明涉及能够抑制蛋白酪氨酸激酶的喹嗪啉和吡啶并嘧啶衍生物。
查看更多